Immuron’s IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19
Immuron Limited (NASDAQ:IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studies…
Immuron Announced in a Publication from the Hebrew University Hadassah Medical Center ‘Augmented Antiviral T Cell Immunity by Oral Administration of Imm-124e in Preclinical Models and a Phase I/iia Clinical Trial: a Method for the Prevention and Treatm…
Immuron Limited (NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, is pleased to notify shareholders of a recent publication describing the potential antiviral benefits of IMM-124E in a mouse model
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
48 Biggest Movers From Friday
Gainers
ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares climbed 58% to close at $5.45 on Friday.